Portola Pharmaceuticals
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch PTLA and buy or sell other stocks, ETFs, and their options commission-free!About PTLA
Portola Pharmaceuticals LLC engages in the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation. It offers Andexxa and Bevyxxa medicines.
CEOJ. Scott Garland, MBA
CEOJ. Scott Garland, MBA
Employees—
Employees—
HeadquartersSouth San Francisco, California
HeadquartersSouth San Francisco, California
Founded2003
Founded2003
Employees—
Employees—
PTLA Key Statistics
Market cap1.42B
Market cap1.42B
Price-Earnings ratio-4.78
Price-Earnings ratio-4.78
Dividend yield—
Dividend yield—
Average volume2.32M
Average volume2.32M
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$31.73
52 Week high$31.73
52 Week low$5.31
52 Week low$5.31
Stock Snapshot
As of today, Portola Pharmaceuticals(PTLA) shares are valued at $18.03. The company's market cap stands at 1.42B, with a P/E ratio of -4.78.
During the trading day, Portola Pharmaceuticals(PTLA) stock saw an opening price of —, a peak of —, and a bottom of —.
Trading activity shows a volume of 0, compared to an average daily volume of 2.32M.
The stock's 52-week range extends from a low of $5.31 to a high of $31.73.
The stock's 52-week range extends from a low of $5.31 to a high of $31.73.
People also own
Based on the portfolios of people who own PTLA. This list is generated using Robinhood data, and it’s not a recommendation.